MX2022010852A - Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc). - Google Patents

Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc).

Info

Publication number
MX2022010852A
MX2022010852A MX2022010852A MX2022010852A MX2022010852A MX 2022010852 A MX2022010852 A MX 2022010852A MX 2022010852 A MX2022010852 A MX 2022010852A MX 2022010852 A MX2022010852 A MX 2022010852A MX 2022010852 A MX2022010852 A MX 2022010852A
Authority
MX
Mexico
Prior art keywords
treatment
cns diseases
sgc
increase
sgc stimulators
Prior art date
Application number
MX2022010852A
Other languages
English (en)
Inventor
Thomas Wai-Ho Lee
Nicholas Robert Perl
Joon Jung
Rajesh R Iyengar
Peter Germano
Kim Tang
Maria D Ribadeneira
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2022010852A publication Critical patent/MX2022010852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de estimulantes de la guanilato ciclasa soluble (sGC), sales farmacéuticamente aceptables de los mismos y formulaciones farmacéuticas o formas de dosificación que comprenden a los mismos, ya sea solos o en combinación con uno o más agentes adicionales, para el tratamien9to de varias enfermedades del SNC, en donde sería deseable un aumento de la estimulación de la sGC, o un aumento en la concentración de óxido nítrico (NO) o de guanosina 3',5'-monofosfato cíclico (GMPc) o de ambos, o un aumento de la expresión de la vía del NO.
MX2022010852A 2016-11-08 2019-05-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc). MX2022010852A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08

Publications (1)

Publication Number Publication Date
MX2022010852A true MX2022010852A (es) 2022-09-27

Family

ID=60452769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005342A MX2019005342A (es) 2016-11-08 2017-11-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc).
MX2022010852A MX2022010852A (es) 2016-11-08 2019-05-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019005342A MX2019005342A (es) 2016-11-08 2017-11-07 Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc).

Country Status (18)

Country Link
US (2) US11690828B2 (es)
EP (1) EP3538096B1 (es)
JP (2) JP7150740B2 (es)
KR (1) KR102475124B1 (es)
CN (1) CN110267658B (es)
AU (2) AU2017359018C1 (es)
BR (1) BR112019009449A2 (es)
CA (1) CA3042548A1 (es)
CL (1) CL2019001256A1 (es)
EA (1) EA201991147A1 (es)
ES (1) ES2972711T3 (es)
IL (1) IL266275B2 (es)
MA (1) MA46752A (es)
MX (2) MX2019005342A (es)
PH (1) PH12019501016A1 (es)
SG (1) SG10202104865UA (es)
TW (1) TWI812601B (es)
WO (1) WO2018089328A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538520A2 (en) * 2016-11-08 2019-09-18 Cyclerion Therapeutics, Inc. Sgc stimulators
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
KR20210031931A (ko) 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
WO2020150698A1 (en) * 2019-01-18 2020-07-23 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
WO2021111419A1 (en) * 2019-12-05 2021-06-10 Cadila Healthcare Limited Modified release pharmaceutical compositions of riociguat
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
CA3240614A1 (en) * 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
IL143691A0 (en) 1998-12-17 2002-04-21 Alza Corp Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
MXPA06001506A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
AU2008296974B2 (en) 2007-09-06 2013-10-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
BRPI1008793A2 (pt) 2009-02-26 2016-03-08 Merck Sharp & Dohme composto, uso de um composto, e, composição farmacêutica
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EA201891416A1 (ru) * 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
JP7050759B2 (ja) * 2016-09-02 2022-04-08 サイクレリオン・セラピューティクス，インコーポレーテッド 縮合二環式ｓｇｃ刺激剤

Also Published As

Publication number Publication date
EA201991147A1 (ru) 2019-11-29
US11690828B2 (en) 2023-07-04
KR20190094167A (ko) 2019-08-12
CN110267658B (zh) 2024-02-02
CA3042548A1 (en) 2018-05-17
TW201822765A (zh) 2018-07-01
TWI812601B (zh) 2023-08-21
EP3538096B1 (en) 2024-02-28
CL2019001256A1 (es) 2019-10-04
BR112019009449A2 (pt) 2019-07-30
AU2023270267A1 (en) 2023-12-07
IL266275B2 (en) 2023-12-01
AU2017359018C1 (en) 2023-12-21
AU2017359018B2 (en) 2023-08-31
US20190343813A1 (en) 2019-11-14
JP2019534327A (ja) 2019-11-28
ES2972711T3 (es) 2024-06-14
CN110267658A (zh) 2019-09-20
AU2017359018A1 (en) 2019-05-30
MX2019005342A (es) 2019-10-02
IL266275B1 (en) 2023-08-01
EP3538096A1 (en) 2019-09-18
EP3538096C0 (en) 2024-02-28
PH12019501016A1 (en) 2019-09-09
WO2018089328A8 (en) 2019-03-28
US20230381153A1 (en) 2023-11-30
MA46752A (fr) 2019-09-18
SG10202104865UA (en) 2021-06-29
IL266275A (en) 2019-06-30
KR102475124B1 (ko) 2022-12-08
JP7150740B2 (ja) 2022-10-11
WO2018089328A1 (en) 2018-05-17
JP2022160605A (ja) 2022-10-19

Similar Documents

Publication Publication Date Title
PH12019501016A1 (en) Treatment of cns diseases with sgc stimulators
PH12019500461A1 (en) Fused bicyclic sgc stimulators
MX2022001565A (es) Formas solidas de un estimulador de guanilato ciclasa soluble (sgc).
PH12020550956A1 (en) Sgc stimulators
PH12019501017A1 (en) Sgc stimulators
MX2019012884A (es) Terapia de combinacion.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2021002321A (es) Nuevos metodos.
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MX2021002322A (es) Nuevos metodos.
MX2018000240A (es) Metodos para tratar el vhc.
CR20230532A (es) ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
WO2015102850A3 (en) Compositions, devices and methods for treating infections
WO2020139163A3 (ru) Комбинация противовирусных средств
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
AR125221A2 (es) Estimuladores de sgc
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті